Show simple item record

dc.contributor.authorAziz, Amir
dc.contributor.authorMusiol, Szymon K
dc.contributor.authorMoody, William E
dc.contributor.authorPickup, Luke
dc.contributor.authorCooper, Rob
dc.contributor.authorLip, Gregory Y H
dc.date.accessioned2024-07-09T14:15:46Z
dc.date.available2024-07-09T14:15:46Z
dc.date.issued2021-05-25
dc.identifier.citationAziz A, Musiol SK, Moody WE, Pickup L, Cooper R, Lip GYH. Clinical prediction of genotypes in hypertrophic cardiomyopathy: A systematic review. Eur J Clin Invest. 2021 Aug;51(8):e13593. doi: 10.1111/eci.13593. Epub 2021 May 25en_US
dc.identifier.issn0014-2972
dc.identifier.eissn1365-2362
dc.identifier.doi10.1111/eci.13593
dc.identifier.pmid33948946
dc.identifier.urihttp://hdl.handle.net/20.500.14200/5082
dc.description.abstractIntroduction: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac condition and the most common cause of sudden cardiac death (SCD) in patients below the age of 35. Genetic testing is a vital part of HCM diagnostics, yet correlation with clinical phenotypes remains complex. Identifying clinical predictors of informative genetic testing may prevent unnecessary investigations and improve cost-effectiveness of services. This article reviews the current literature pertinent to identifying such predictors. Methods: Five literature databases were screened using a suitably designed search strategy. Studies investigating the correlation between having a positive genetic test for HCM and a range of clinical and radiological parameters were included in the systematic review. Results: Twenty-nine observational studies of a total of 9,486 patients were included. The main predictors of informative genetic testing were younger age, higher septal thickness, reverse septal curvature, family history of HCM and SCD and the absence of hypertension. Two externally validated scoring systems have also been developed: the Mayo and Toronto scores. Novel imaging markers and complex algorithmic models are emerging predictors. Conclusion: Using clinical predictors to decide whom to test is a feasible alternative to investigating all comers. Nonetheless, currently there is not enough evidence to unequivocally recommend for or against this strategy. Further validation of current predictors and identification of new ones remain open research avenues.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.urlhttp://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2362en_US
dc.rights© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
dc.subjectCardiologyen_US
dc.titleClinical prediction of genotypes in hypertrophic cardiomyopathy: a systematic review.en_US
dc.typeArticleen_US
dc.source.journaltitleEuropean Journal of Clinical Investigationen_US
dc.source.volume51
dc.source.issue8
dc.source.beginpagee13593
dc.source.endpage
dc.source.countryEngland
rioxxterms.versionNAen_US
dc.contributor.trustauthorMoody, William
dc.contributor.departmentCardiologyen_US
dc.contributor.roleMedical and Dentalen_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record